Back

Four-month treatment with long-acting glucagon-like peptide-1 receptor agonists (GLP-1) or sodium-glucose co-trasporter-2 inhibitors (SGLT-2i) improves vascular function in type 2 diabetes mellitus

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Medical management and risk factors Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Ignatios Ikonomidis

National & Kapodistrian University of Athens, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis
Professor M. Evans (Cardiff, GB)
Abstract Slides
Presentation thumbnail
Predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based cohort study
Mr T. Lee (Hong Kong, HK)
Abstract Slides
Presentation thumbnail
Celiprolol to prevent arterial events in patients with vascular Ehlers-Danlos and neither symptomatic nor silent arterial event. A retrospective cohort study from the French national reference center
Professor T. Mirault (Paris, FR)
Abstract Slides
Presentation thumbnail
Inequalities in accessing quality healthcare, does insurance play a role? retrospective analysis of aortic emergencies from national inpatient sample 2019.
Doctor S. Vohra (New York City, US)
Abstract Slides

Access the full session

Session thumbnail
Medical management and risk factors

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources